5 Key Takeaways

• 1

  Distribution barriers may reduce biologic drug survival among patients with moderate-to-severe psoriasis.

• 2

  Patients reporting medication distribution problems were more likely to discontinue biologic therapy.

• 3

  Adalimumab was the most frequently prescribed biologic, followed by secukinumab and ustekinumab.

• 4

  Approximately one-third of patients reported their biologic medication was out of stock during therapy.

• 5

  The study acknowledged limitations due to its retrospective design and small sample size.